Poster: AML-389 Phase 1/2 Study of SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients With IDH1/2-Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial

Authors :: Giovanni Martinelli
Armando Santoro
Carlo Gambacorti-Passerini
Susana Vives Polo
Scott R. Solomon
Sudipto Mukherjee
Ewa Lech-Maranda
Moshe Yair Levy
Agnieszka Wierzbowska
María Calbacho-Robles
Giovanni Marconi
Maria Benedetta Giannini
Isabel Cano
Laura Torres Miñana
Evelyn Acuña-Cruz
Noemi Angelosanto
Tariq I. Mughal
Antonio Galleu
Simona Blotta
Farhad Ravandi
Pau Montesinos
Source :: Clinical Lymphoma Myeloma and Leukemia. 22:S137
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Full Text Access

Tools